Non-Interventional Real-Life Study of Effectiveness, Safety, Adherence, and Health-Related Quality of Life in Adult Patients receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or Emtricitabine/Tenofovir alafenamide (F/TAF) or Rilpivirine/Emtricitabine/Tenofovir alafenamide (R/F/TAF) for HIV-1 Infection in Germany (TAFNES)

05/10/2015
22/02/2024
EU PAS number:
EUPAS11010
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

amd-1-GS-DE-292-1912-FINAL-COMPLETE

English (1.48 MB - PDF) View document
Updated protocol

GS-DE-292-1912-appendix-16.1.1-protocol-amendment 2_f-redact

First published: 22/02/2024
English (1.42 MB - PDF) View document
Study results
Study results

GS-DE-292-1912-csr-body final_f-redact

English (1.89 MB - PDF) View document
Study report
Other information